about
Expression Level of Genes Coding for Cell Adhesion Molecules of Cadherin Group in Colorectal Cancer Patients.A new form of amphotericin B - the complex with copper (II) ions - downregulates sTNFR1 shedding and changes the activity of genes involved in TNF-induced pathways: AmB-Cu2+ downregulates sTNFR1 shedding and changes the activity of genes involved inPorcine endogenous retrovirus infection changes the expression of inflammation-related genes in lipopolysaccharide-stimulated human dermal fibroblasts.Amphotericin B-copper (II) complex alters transcriptional activity of genes encoding transforming growth factor-beta family members and related proteins in renal cells.Epigenetic silencing of endothelin-3 in colorectal cancer.Influence of Adalimumab on the Expression Profile of Genes Associated with the Histaminergic System in the Skin Fibroblasts In Vitro.Transforming growth factor β-related genes in human retinal pigment epithelial cells after tacrolimus treatment.Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions.Impact of fluoride and a static magnetic field on the gene expression that is associated with the antioxidant defense system of human fibroblasts.Psoriasis Treatment Changes the Expression Profile of Selected Caspases and their Regulatory MicroRNAsThe analysis of the therapeutic potential of ustekinumab in psoriasis vulgaris treatment.Changes in the Expression Profile of JAK/STAT Signaling Pathway Genes and Mirnas Regulating their Expression Under the Adalimumab TherapyAssessment of transcriptional activity genes associated with the IL-17 signaling pathway in skin fibroblasts under the influence of adalimumabEvaluation of changes in expression pattern of oxidative stress genes under the influence of adalimumabThe influence of adalimumab on the expression profile of mRNAs and miRNAs related to the IL-12 and IL-23 signal pathsInterplay between miRNAs and Genes Associated with Cell Proliferation in Endometrial Cancer
P50
Q35887522-9275985C-6F73-4F51-B462-B098042388ABQ38740153-86C36A62-DAEE-4F7F-AFF8-86F436DDA834Q42260002-D77479A3-051D-482E-A92C-E069C8C3A5CBQ47412750-C1736675-C057-4E24-BFB2-A96FE9E2F07AQ48281326-34C8ACC2-1AAB-4596-9D4D-3779F7D40FC8Q50296996-71390724-6FFC-416C-AE5B-4B7D8D905FFBQ51666930-A8F268F5-007C-4BCF-989E-807CE1FBCD40Q52642173-EDFBE618-8AE2-4314-962E-1C2F55493574Q52720659-5B96A017-50DA-46EF-9E14-E2B508A568AFQ57280000-390CAE82-69D3-4F69-ACB6-4705847C4704Q68097920-BBD0AD85-0303-4968-8FED-B189C2330E6AQ90605539-82F30564-0CB5-4A10-A968-4D095E54C095Q90667007-A7503DE3-CCEA-415A-88D2-3637EED614BDQ91003424-7A9C540F-54BA-4901-AC22-7D60C250AB71Q91304229-4BF120B7-974C-4C0F-9BCD-0E98373EE4BEQ91645027-F4D56428-CE8F-4E2C-A732-B25B8DD448D5
P50
description
researcher ORCID ID = 0000-0002-2504-6289
@en
wetenschapper
@nl
name
Celina Kruszniewska-Rajs
@ast
Celina Kruszniewska-Rajs
@en
Celina Kruszniewska-Rajs
@es
Celina Kruszniewska-Rajs
@nl
type
label
Celina Kruszniewska-Rajs
@ast
Celina Kruszniewska-Rajs
@en
Celina Kruszniewska-Rajs
@es
Celina Kruszniewska-Rajs
@nl
prefLabel
Celina Kruszniewska-Rajs
@ast
Celina Kruszniewska-Rajs
@en
Celina Kruszniewska-Rajs
@es
Celina Kruszniewska-Rajs
@nl
P31
P496
0000-0002-2504-6289